Cargando…

KRAS: A Druggable Target in Colon Cancer Patients

Mutations in KRAS are among the most frequent aberrations in cancer, including colon cancer. KRAS direct targeting is daunting due to KRAS protein resistance to small molecule inhibition. Moreover, its elevated affinity to cellular guanosine triphosphate (GTP) has made the design of specific drugs c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Negri, Francesca, Bottarelli, Lorena, de’Angelis, Gian Luigi, Gnetti, Letizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027058/ https://www.ncbi.nlm.nih.gov/pubmed/35456940 http://dx.doi.org/10.3390/ijms23084120

Ejemplares similares

Microsatellite instability in colorectal cancer
por: Gian, Luigi de’Angelis, et al.
Publicado: (2018)

Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy
por: Lorena, Bottarelli, et al.
Publicado: (2018)

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
por: Zhu, Chunxiao, et al.
Publicado: (2022)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021)

Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series
por: Negri, Francesca, et al.
Publicado: (2019)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology?
por: Negri, Francesca, et al.
Publicado: (2023)

The Missing Link between (Un)druggable and Degradable KRAS
por: De Vita, Elena, et al.
Publicado: (2020)

Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes
por: Gaiani, Federica, et al.
Publicado: (2021)

Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer
por: Laghi, Luigi, et al.
Publicado: (2020)

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer
por: Seguin, Laetitia, et al.
Publicado: (2018)

Druggable Targets of Squamous Cell Lung Cancer
por: Kim, Cheol Hyeon
Publicado: (2013)

The Diverse Potential of Gluten from Different Durum Wheat Varieties in Triggering Celiac Disease: A Multilevel In Vitro, Ex Vivo and In Vivo Approach
por: Gaiani, Federica, et al.
Publicado: (2020)

Cysteine metabolic circuitries: druggable targets in cancer
por: Bonifácio, Vasco D. B., et al.
Publicado: (2020)

Oral Bacterial Microbiota in Digestive Cancer Patients: A Systematic Review
por: Reitano, Elisa, et al.
Publicado: (2021)

Mitochondrial Potassium Channels as Druggable Targets
por: Wrzosek, Antoni, et al.
Publicado: (2020)

Reading Cancer: Chromatin Readers as Druggable Targets for Cancer Treatment
por: Mio, Catia, et al.
Publicado: (2019)

Antimicrobial Challenge in Acute Care Surgery
por: Schena, Carlo Alberto, et al.
Publicado: (2022)

Druggable genetic targets in endometrial cancer
por: Lehrer, Steven, et al.
Publicado: (2022)

Toxoplasmosis: Current and Emerging Parasite Druggable Targets
por: Hajj, Rana El, et al.
Publicado: (2021)

Novel Biomarkers and Druggable Targets in Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Role of the intestinal microbiome in colorectal cancer surgery outcomes
por: Lauka, Lelde, et al.
Publicado: (2019)

Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report
por: Minari, Roberta, et al.
Publicado: (2020)

Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment?
por: Choi, Seul-Ki, et al.
Publicado: (2019)

Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab
por: Bersanelli, Melissa, et al.
Publicado: (2019)

Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer
por: Nakhjavani, Maryam, et al.
Publicado: (2019)

Clinical approach to the patient with acute gastrointestinal bleeding
por: Federica, Gaiani, et al.
Publicado: (2018)

NF-κB: A Druggable Target in Acute Myeloid Leukemia
por: Di Francesco, Barbara, et al.
Publicado: (2022)

Druggable Targets and Compounds with Both Antinociceptive and Antipruritic Effects
por: Weng, Hao-Jui, et al.
Publicado: (2022)

Richter Syndrome: From Molecular Pathogenesis to Druggable Targets
por: Mouhssine, Samir, et al.
Publicado: (2022)

Intestinal Enteroendocrine Cells: Present and Future Druggable Targets
por: Atanga, Roger, et al.
Publicado: (2023)

Targeting KRAS in Pancreatic Cancer
por: Cowzer, Darren, et al.
Publicado: (2022)

The Druggable Pocketome of Corynebacterium diphtheriae: A New Approach for in silico Putative Druggable Targets
por: Hassan, Syed S., et al.
Publicado: (2018)

A receptor-mediated landscape of druggable and targeted nanomaterials for gliomas
por: Di Filippo, Leonardo Delello, et al.
Publicado: (2023)

Mucosal microbiota of intestinal polyps reveals putative biomarkers of colorectal cancer
por: Mangifesta, Marta, et al.
Publicado: (2018)

Case report: Successful endoscopic removal of a large rectal foreign body
por: Bosi, Simone, et al.
Publicado: (2020)

Targeting the untargetable KRAS in cancer therapy
por: Liu, Pingyu, et al.
Publicado: (2019)

Therapeutic Targets of KRAS in Colorectal Cancer
por: Rahman, Shafia, et al.
Publicado: (2021)

Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
por: Montor, Wagner Ricardo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7qvkfur26skk0qssjmq2c3cmi2